Bayer eyes launch of menopause relief, heart drugs this year
Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of ...
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...
Pharmabiz1d
BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval
BridgeBio Pharma’s Beyonttra to treat transthyretin-mediated amyloid cardiomyopathy receives Japanese approval: Palo Alto, California Monday, March 31, 2025, 17:00 Hrs [IST] Bri ...
BridgeBio announces Japanese MHLW approved acoramidis for treating ATTR-CM
BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...
The Pharma Letter5d
BridgeBio’s Beyonttra approved in Japan
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
Sportskeeda4d
Bayonetta director Hideki Kamiya seemingly defends Assassin's Creed Shadows online
Ex-Platinum Games employee Hideki Kamiya has seemingly joined the debate surrounding Assassin's Creed Shadows.
Business Insider5d
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan. “There is significant need for new treatment options for ATTR-CM, a progressive ...
Morningstar5d
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
JAMA Cardiol. 2024 Dec 4:e244102. Beyonttra is an orally administered near-complete (≥90%) stabilizer of transthyretin (TTR) indicated for the treatment of wild-type or variant transthyretin ...
Toronto Star5d
Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved in Japan to Treat ATTR-CM
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated In the Japanese Phase 3 study, 0% mortality was reported over the 30 ...